Menu

Recent Interviews

Dirk Graszt, CEO, Clean Logistics SE

Dirk Graszt
CEO | Clean Logistics SE
Trettaustr.32, 21107 Hamburg (DE)

info@cleanlogistics.de

+49-4171-6791300

Interview Clean Logistics: Hydrogen challenge to Daimler + Co.


Matthew Salthouse, CEO, Kainantu Resources

Matthew Salthouse
CEO | Kainantu Resources
3 Phillip Street #19-01 Royal Group Building, 048693 Singapore (SGP)

info@krl.com.sg

+65 6920 2020

Interview Kainantu Resources: "We hold the key to growth in the Asia-Pacific region".


Justin Reid, President and CEO, Troilus Gold Corp.

Justin Reid
President and CEO | Troilus Gold Corp.
36 Lombard Street, Floor 4, M5C 2X3 Toronto, Ontario (CAN)

info@troilusgold.com

+1 (647) 276-0050

Interview Troilus Gold: "We are convinced that Troilus is more than just a mine".


20. April 2021 | 09:45 CET

Varta, Sierra Growth, CureVac - Clear signals!

  • Investments
Photo credits: pixabay.com

Sometimes, for various reasons, it takes longer before the positive developments of a Company are absorbed by the market and thus provide for price gains. It is currently similar to the precious metal gold, which is still in the consolidation phase. The facts such as national debt, inflation fears and the ultra-loose monetary policy of the central banks speak another clear language.

time to read: 3 minutes by Stefan Feulner
ISIN: DE000A0TGJ55 , CA8263191055 , NL0015436031


 

Author

Stefan Feulner

The native Franconian has more than 20 years of stock exchange experience and a broadly diversified network.
He is passionate about analyzing a wide variety of business models and investigating new trends.

About the author


Sierra Growth - Rocket launch

An interesting story is the newly founded mineral oil exploration Company Sierra Growth, searching for metals silver, copper, gold, and molybdenum. The Canadian Company has focused on exploring projects in the Andean nation of Peru and primarily on three mineral properties in central and western Nevada. The properties are owned by experienced rights holders with a proven track record of exploration in Nevada and all share the same characteristics. Significant preliminary work has been done in the past, but this has generally been limited to surface or near-surface exploration, leaving much exploration potential, particularly at depth. To this end, excellent infrastructure is in place: Power, water, and utilities are available nearby in local mining towns. Because of this, all three properties can be brought to drill-ready status relatively quickly.

The Company announced successful prospect evaluations in the middle of last week. They were so encouraging that management believes that the subsequent phases of exploration will delineate high-quality exploration targets. The package of prospects has excellent potential for the discovery of a significant mineral deposit. Grab samples at the Mildred concession mine area detected 26.6 g/t gold and 78.6 g/t silver and elsewhere detected 667 g/t silver and 0.41 g/t gold. Values of 646 g/t silver and 0.53 g/t gold were also found in the Betty East mine area. Sierra Growth's shares are traded in Frankfurt as well as Toronto. Due to the management experience, the Company can be expected to do well in the long term. However, the development is only at the beginning.

CureVac - Off to Switzerland

CureVac had already started the rolling approval process for the vaccine candidate at the European Medicines Agency (EMA) in February and expects approval for the EU in June, depending on the clinical data. Now, the Tübingen-based German pharmaceutical Company has started a rolling approval process for its Covid-19 vaccine candidate in Switzerland. The marketing authorization application has been submitted to Swissmedic, the drug agency, according to the Company. The rolling review process is an expedited process in which necessary data can be submitted and reviewed as it becomes available to shorten the time to approval.

The duration of the rolling review process depends on the completeness of data submitted by CureVac and the results of the clinical trials, according to Swissmedic.
So far, vaccines from BioNTech, Moderna and Johnson & Johnson have been approved in Switzerland. An application for approval from AstraZeneca is also currently under review by Swissmedic. In early February, the Swiss government had signed a contract with CureVac for the supply of 5 million vaccine doses. This contract is based on the supply agreement between the European Commission and the Company.

Varta - Full in six minutes!

In the past, six minutes was the time it took for a well-poured draft beer. Now the Varta cell 21700 is to be completely charged and discharged in the same time. So far, this would be unique on the market and is expected to significantly impact the Company's sales and profit development in the future. Thus, according to Varta CEO Herbert Schein, the new 21700 cell could add a third business segment. In 2024, Varta plans to produce between 100 and 200 million 21700 battery cells per year. The 21700 battery cell will initially be used primarily in high-performance electric cars. However, the key difference between this and other battery cells on the market is that the 21700 format battery cell, i.e. 2.1 cm in diameter and 7 cm long, will not be used as the sole traction battery. Instead, Varta is aiming to use it as a booster in premium and sports vehicles. Varta's share price does not currently reflect the Company's positive outlook. Further price losses towards EUR 100 could follow a drop below the current support zone at EUR 120.


Author

Stefan Feulner

The native Franconian has more than 20 years of stock exchange experience and a broadly diversified network.
He is passionate about analyzing a wide variety of business models and investigating new trends.

About the author



Conflict of interest & risk note

In accordance with §34b WpHG we would like to point out that Apaton Finance GmbH as well as partners, authors or employees of Apaton Finance GmbH may hold long or short positions in the aforementioned companies and that there may therefore be a conflict of interest. Apaton Finance GmbH may have a paid contractual relationship with the company, which is reported on in the context of the Apaton Finance GmbH Internet offer as well as in the social media, on partner sites or in e-mail messages. Further details can be found in our Conflict of Interest & Risk Disclosure.


Related comments:

14. October 2021 | 07:46 CET | by Stefan Feulner

SAP, Kleos Space, Ballard Power - Igniting like a rocket

  • Investments

The storage and processing of data will be one of the themes of our society for the coming years. Big Data will create scientific advances and innovations, increasing the competitiveness of both science and companies across industries. Already today, innovative startups are working on the processing of larger amounts of data using artificial intelligence. The potential is enormous, the predicted growth rates gigantic.

Read

11. October 2021 | 11:30 CET | by Armin Schulz

Allianz, wallstreet:online, Commerzbank - Quo vadis stock markets?

  • Investments

The markets are highly nervous at the moment. First, the Corona numbers went up again, then the Chinese real estate giant Evergrande was on the verge of collapse, and the supply chains are still not back in step. The result was falling indexes. That automatically leads to more fear, as the Fear and Greed Index also showed. Last week, the market calmed down slightly, and the fear index dropped from 27 to 34 points. In Germany, there is also the fact that more people have dabbled in equity investments due to a lack of interest rates. According to the Global Wealth Report, the purchase of securities grew by 65%. Many of the newly added shareholders know only rising stock markets. Consolidation would not hurt the market. On the other hand, there is hardly any alternative to investing money at the moment. It remains exciting.

Read

11. October 2021 | 10:26 CET | by Stefan Feulner

Deutsche Post, Memiontec, Bayer - Here is where the action is

  • Investments

After heavy losses in recent weeks - the DAX losing more than 1,200 points at its peak and briefly slipping below the 15,000-point mark - the mood is brightening again. The German benchmark index, now made up of 40 members, is back on track for a year-end rally despite concerns about stagflation. The 16,000 peak beckons once again. Individual stocks are likely to outperform in the final weeks of the stock market year based on the recently reported fundamental data.

Read